文献速递心脑血管急症重症综合管理与镇静镇痛

利伐沙班与达肝素治疗肿瘤相关血栓栓塞:一项随机试验

Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial.
PubMed 文献 · Chest · 2021-10-08
一句话结论在活动性肿瘤相关静脉血栓栓塞患者中,利伐沙班3个月复发性静脉血栓栓塞累积发生率6.4% vs 达肝素10.1%,但样本量不足以达到预设的非劣效标准。

该随机开放标签非劣效试验纳入158例活动性肿瘤合并近端深静脉血栓和/或肺栓塞的患者,随机接受治疗剂量利伐沙班或达肝素治疗3个月。主要终点为3个月复发性静脉血栓栓塞(症状性或偶然发现的深静脉血栓/肺栓塞及肺血管或静脉梗阻加重)的累积发生率,利伐沙班组6.4% vs 达肝素组10.1%(SHR 0.75,95%CI 0.21-2.66)。大出血累积发生率1.4% vs 3.7%(SHR 0.36,95%CI 0.04-3.43),大出血或临床相关非大出血12.2% vs 9.8%(SHR 1.27,95%CI 0.49-3.26),死亡率25.7% vs 23.8%(HR 1.05,95%CI 0.56-1.97)。作者认为样本量不足以达到预设非劣效标准,但疗效与安全性结果与既往DOAC报道一致。

要点

  • 活动性肿瘤合并近端深静脉血栓和/或肺栓塞患者,利伐沙班3个月复发性静脉血栓栓塞累积发生率6.4%(4例)vs 达肝素10.1%(6例),SHR 0.75(95%CI 0.21-2.66)。
  • 大出血累积发生率利伐沙班1.4%(1例)vs 达肝素3.7%(3例),SHR 0.36(95%CI 0.04-3.43)。
  • 大出血或临床相关非大出血累积发生率利伐沙班12.2%(9例)vs 达肝素9.8%(8例),SHR 1.27(95%CI 0.49-3.26)。
  • 全因死亡利伐沙班组19例(25.7%)vs 达肝素组20例(23.8%),HR 1.05(95%CI 0.56-1.97)。
  • 作者认为样本量不足以达到预设非劣效标准,但疗效与安全性结果与既往DOAC报道一致。

适用人群与场景

  • 活动性肿瘤合并近端深静脉血栓、肺栓塞或两者兼有的患者;158例随机,利伐沙班组74例、达肝素组84例,平均年龄69.4岁,115例(76.2%)为转移性疾病。

处置流程与药物剂量

  • 利伐沙班或达肝素均按治疗剂量给药,疗程3个月。

研究设计与关键结果

  • 随机开放标签非劣效试验,158例活动性肿瘤合并近端深静脉血栓和/或肺栓塞患者随机接受利伐沙班(74例)或达肝素(84例)治疗3个月。
  • 主要终点(3个月复发性静脉血栓栓塞,含症状性或偶然发现的深静脉血栓/肺栓塞及肺血管或静脉梗阻加重)在利伐沙班组4例、达肝素组6例,意向治疗与符合方案人群累积发生率均为6.4% vs 10.1%,SHR 0.75(95%CI 0.21-2.66)。
  • 大出血利伐沙班组1例 vs 达肝素组3例,累积发生率1.4% vs 3.7%,SHR 0.36(95%CI 0.04-3.43)。
  • 大出血或临床相关非大出血利伐沙班组9例 vs 达肝素组8例,累积发生率12.2% vs 9.8%,SHR 1.27(95%CI 0.49-3.26)。
  • 全因死亡利伐沙班组19例(25.7%)vs 达肝素组20例(23.8%),HR 1.05(95%CI 0.56-1.97)。

证据类型、等级与局限

  • 证据类型:随机开放标签非劣效试验;作者认为样本量不足以达到预设的非劣效标准。
  • 局限:原文报告样本量不足以达到预设非劣效标准,但疗效与安全性结果与既往DOAC报道一致。

对床旁实践的改变

  • 作者认为,尽管样本量不足以达到预设非劣效标准,利伐沙班与达肝素相比的疗效和安全性结果与既往DOAC报道一致。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Direct oral anticoagulants (DOACs) are an alternative to low-molecular-weight heparin for treating cancer-associated VTE.

RESEARCH QUESTION: Is rivaroxaban as efficient and safe as dalteparin to treat patients with cancer-associated VTE?

STUDY DESIGN AND METHODS: In a randomized open-label noninferiority trial, patients with active cancer who had proximal DVT, pulmonary embolism (PE), or both were assigned randomly to therapeutic doses of rivaroxaban or dalteparin for 3 months. The primary outcome was the cumulative incidence of recurrent VTE, a composite of symptomatic or incidental DVT or PE, and worsening of pulmonary vascular or venous obstruction at 3 months.

RESULTS: Of 158 randomized patients, 74 and 84 patients were assigned to receive rivaroxaban and dalteparin, respectively. Mean age was 69.4 years, and 115 patients (76.2%) had metastatic disease. The primary outcome occurred in 4 and 6 patients in the rivaroxaban and dalteparin groups, respectively (both the intention-to-treat and per-protocol populations: cumulative incidence, 6.4% vs 10.1%; subdistribution hazard ratio [SHR], 0.75; 95% CI, 0.21-2.66). Major bleeding occurred in 1 and 3 patients in the rivaroxaban and dalteparin groups, respectively (cumulative incidence, 1.4% vs 3.7%; SHR, 0.36; 95% CI, 0.04-3.43). Major or clinically relevant nonmajor bleeding occurred in 9 and 8 patients in the rivaroxaban and dalteparin groups, respectively (cumulative incidence, 12.2% vs 9.8%; SHR, 1.27; 95% CI, 0.49-3.26). Overall, 19 patients (25.7%) and 20 patients (23.8%) died in the rivaroxaban and dalteparin groups, respectively (hazard ratio, 1.05; 95% CI, 0.56-1.97).

INTERPRETATION: In this trial comparing rivaroxaban and dalteparin in the treatment of cancer-associated VTE, the number of patients was insufficient to reach the predefined criteria for noninferiority, but efficacy and safety results were consistent with those previously reported with DOACs. An updated meta-analysis of randomized trials comparing DOACs with low-molecular-weight heparin in patients with cancer-associated VTE is provided.

TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT02746185; URL: www.

CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Planquette B, Bertoletti L, Charles-Nelson A, et al. Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial. Chest. 2021. PMID: 34627853. doi:10.1016/j.chest.2021.09.037

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。